PATIENTS
Benefiting from the most efficient or adapted therapy to cure from disease and/or to be cured with the best quality of life during treatment
ACOBIOM
Providing innovative and non-invasive Blood-based In Vitro Diagnostic to predict patient response to a certain therapy
CLINICS & HOSPITALS
Making a diagnosis, treating, providing medical follow-up with the objective to personalize patient’s medical care in taking into account individual differences
GemciTest®
The first diagnostic to predict the patient response in pancreatic cancer treatment
PANCREATIC CANCER
A rare and “silent” disease with no symptom early on, difficult to diagnose and cure.
DIAGNOSTIC
A blood-based molecular test (RUO diagnostic) to predict patient’s therapeutic response
GEMCITABINE
The less toxic and expensive chemotherapy in pancreatic cancer treatment
BLOOD RNA-SIGNATURE
A combination of biomarkers to identify patients most likely to benefit from gemcitabine
To improve the patient’s quality of life during pancreatic cancer treatment
Our Expertises
Acobiom is an innovative biotechnology company specialized in the discovery of new biomarkers and in the development of innovative diagnostics.
BIOMARKERS
Analyses of biological phenotypes; investigation of gene expression changes; Identification & validation of acid nucleic (DNA, RNA, miRNA, small RNA, coding & non coding RNA) biomarkers based on Sequencing/NGS & PCR technologies.
BIOINFORMATICS
Treatments & analyses of sequencing/omics big data through a proprietary suite of Bioinformatic & Biostatistic tools; Development of a 21,000 Human RNA-Seq database, in-silico investigations through public & proprietary databases.
PRECISION MEDICINE
Biomarkers and diagnostics “to optimize a specific preventive, diagnostic or therapeutic intervention in a given subpopulation of patients, which would most likely to benefit from it”.
GENOMICS
A unique scientific and technical expertise associated with 20-year experience in genomics & transcriptomics, in sequencing/NGS & PCR technologies, in performing RNA-Seq / ChIP-seq analyses, and PCR / qPCR / qRT-PCR experiences.
Latest News
How Artificial Intelligence can help to the development of diagnostics dedicated to Precision Medicine
Generating sequencing data from patient blood samples became easy to perform in clinical trials. But, analyzing the huge amount of genomic or transcriptomic data and extracting the key biomarkers associated[…]
Read more
The Cancer Center (CGFL) of Dijon evaluates the Acobiom’s GemciTest in clinics
The Cancer Center (CGFL) of Dijon (France) launches a clinical study in 2018 to evaluate the prognostic value of on the overall survival and response to major treatments in patients[…]
Read more
Acobiom became partner of European clinical project focused on Bipolar disorders
Acobiom became partner of the R-Link European program, which brings together 15 partners from 9 countries to develop a personalized approach to the medical care of patients suffering from bipolar[…]
Read moreABOUT ACOBIOM
Since its foundation, Acobiom has always been at the forefront of Medical Innovation.
Acobiom was founded by Didier Ritter and Dr David Piquemal under the name « Skuldtech » to promote the gene expression profile (transcriptome) approach with the objective to discover RNA biomarkers, to develop diagnostics, and to improve the patient’s medical care.
FOR MORE INFORMATION
